Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 7,884 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non intervention study Clear all

Conditions: Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital, Florida; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Infertility, Female
Interventions: Endometrial biopsy; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Substance Use Disorders, Pain
Interventions: SBIRT-PM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 9
States / cities: New Haven, Connecticut • West Haven, Connecticut • Augusta, Maine + 6 more

Conditions: Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions: cyclophosphamide, fludarabine phosphate, vincristine sulfate, prednisone, rituximab, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Critical Illness
Interventions: EHR-Based Intervention A, EHR-Based Intervention B; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Albemarle, North Carolina • Charlotte, North Carolina • Lincolnton, North Carolina + 3 more

Conditions: Nicotine Addiction, Smoking Cessation
Interventions: Quit Center cessation program; Behavioral
Lead sponsor: Quit Center LLC; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Diabetic Foot Ulcer
Interventions: AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care; Other · Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more

Conditions: Autism Spectrum Disorders, Normal Hearing, Normal Intelligence, Exhibit Self- Stimulating or Ritualistic Behaviors
Interventions: ProFoveate; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, CXCR1/2 Inhibitor SX-682, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sensitivity, Tooth
Interventions: TOMs of Maine Sensitive SLS Free Xtra Fresh, Colgate Cavity protection toothpaste; Device · Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Kidney Stones
Interventions: Ureteroscopy using the 6.3 Fr f-URS hugemed, Hugemed 6.3 Fr f-URS; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: College Student Drinking
Interventions: college drinker's check up, Protective Behavioral Strategies Intervention, Ecological Momentary Intervention; Behavioral
Lead sponsor: James M. Henson; Other
Eligibility: 18 Years to 25 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Carson, California • Fort Collins, Colorado • Albuquerque, New Mexico + 2 more

Conditions: Physical Activity
Interventions: Step 1: PA Monitor, Step 1: PA Monitor + Text, Step 2: PA Monitor with Calls, Step 2: PA Monitor with Meetings, Step 2: PA Monitor + Texts with Calls, Step 2: PA Monitor + Texts with Meetings, Step 3: PA Monitor; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne
Interventions: Skin biopsy, Blood draw; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Melanoma
Interventions: Cyclophosphamide, Fludarabine, Interleukin-2, TIL Product; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: SCAR
Interventions: Blood or Saliva; Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Not listed
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Image Guided Stereotactic Ablative Radiotherapy; Radiation
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: electronic medical record, Integrated Approach to Care, usual care, Shared Decision Making, school based care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 1,040 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Charlotte, North Carolina

Conditions: Hematologic Malignancy, Hematopoietic/Lymphoid Cancer, Blood Cancer
Interventions: Positive Psychology Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastroesophageal Cancer
Interventions: Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy; Radiation · Drug · Procedure + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 341
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more

Conditions: IVC Filters
Interventions: Prospective Chart Review; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Atenolol (β-blocker); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Study to Validate Simple Acute Coronary Syndrome Score

Transcriptomic Evaluation of Endometrial Receptivity

Pragmatic RCT of SBIRT-PM

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Prognosticating Outcomes and Nudging Decisions With Electronic Records in the ICU Trial

Evaluation of a Smoking Cessation Program for Long-Term Abstinence

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity.

Surgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope

Efficacy and Mechanisms of Technology-based Behavioral Interventions

Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN

Positive Psychology Intervention In HSCT

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Excimer Laser Assisted IVC Filter Retrieval

Genetic Determinants of Response to Beta Blockade